Bratisl Lek Listy. 2022;123(3):153-159. doi: 10.4149/BLL_2022_026.
The aim of this study was to establish a set of hospitalised patients with persistent pulmonary hypertension of the newborn (PPHN) by using retrospective analysis according to gestational age, position during childbirth, type of childbirth, dosage and length of the treatment by inhaled nitric oxide (NO) and application of inotropic agents as well as interindividual specifics and the background of PPHN.
Our cohort consisted of 11 newborns who were hospitalised in Neonatal Department of Intensive Medicine between 1st January 2017 and 31st December 2019. Four of these patients were born prematurely. Only two out of eleven patients were born vaginally. Nine of the newborns were diagnosed with secondary PPHN, in three of these cases it was caused by infection. The highest dose of inhaled nitric oxide used was 40 ppm.
The focus of this paper was the therapeutic use of nitric oxide, its various applications and the effect of it on pulmonary circulation of the newborn. Inhaled NO is a selective pulmonary vasodilator used as a therapeutic agent for PPHN of the newborn. The conclusions of this paper can be beneficial in the development of better therapeutic strategies for patients with PPHN in the future (Tab. 3, Fig. 1, Ref. 40).
本研究旨在根据胎龄、分娩时的体位、分娩方式、吸入一氧化氮（NO）的剂量和治疗持续时间、正性肌力药物的应用以及个体差异和新生儿持续性肺动脉高压（PPHN）的背景，通过回顾性分析确定一组住院的新生儿持续性肺动脉高压患者。
我们的队列包括 2017 年 1 月 1 日至 2019 年 12 月 31 日期间在新生儿重症监护病房住院的 11 名新生儿。其中 4 名患儿早产，11 名患儿中仅有 2 名经阴道分娩。9 名新生儿被诊断为继发性 PPHN，其中 3 例由感染引起。使用的吸入一氧化氮最高剂量为 40ppm。
本文的重点是一氧化氮的治疗应用及其对新生儿肺循环的影响。吸入 NO 是一种选择性肺血管扩张剂，用作新生儿 PPHN 的治疗药物。本文的结论可以为未来 PPHN 患者的更好治疗策略的发展提供有益的参考（表 3、图 1、参考文献 40）。
